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Sciences Department, MedImmune, Gaithersburg, MarylandABSTRACT A monoclonal antibody solution displays an increase in low shear rate viscosity upon aggregation after prolonged
incubation at 40C. The morphology and interactions leading to the formation of the aggregates responsible for this non-New-
tonian character are resolved using small-angle neutron scattering.Our data showaweak repulsive barrier before proteins aggre-
gate reversibly, unless a favorable contact with high binding energy occurs. Two types of aggregates were identified after
incubation at 40C: oligomerswith radius of gyration ~10 nmand fractal submicrometer particles formed by a slow reaction-limited
aggregation process, consistent with monomers colliding many times before finding a favorable strong interaction site. Before
incubation, these antibody solutions are Newtonian liquids with no increase in low shear rate viscosity and no upturn in scattering
at low wavevector, whereas aggregated solutions under the same conditions have both of these features. These results
demonstrate that fractal submicrometer particles are responsible for the increase in low shear rate viscosity and low wavevector
upturn in scattered intensity of aggregated antibody solutions; both are removed from aggregated samples by filtering.INTRODUCTIONThe development of biotherapeutics, in particular mono-
clonal antibodies (mAbs), has rapidly increased due to their
binding specificity to antigens and their efficacy in treating
various diseases (1,2). However, there are concerns about
their immunogenicity profile when protein aggregates are
formed (3–5). In addition, high mAb concentrations are
necessary to minimize the volume required for subcutane-
ous injection, leading to high viscosity and greater propen-
sity for aggregation (6).
The interactions and structure of aggregated systems and
their constituent units can be characterized using small-
angle neutron scattering (SANS). In particular, SANS has
been used to study several proteins, including lysozyme
(7–10), cytochrome c (9,11), serum albumin (12–15), and
insulin (16). SANS has yielded important insights into the
conformation of proteins (17), clustering (8,10), and pro-
tein-protein interactions (9,18). In many of these studies,
molecular simulations have been an important tool for
data interpretation and analysis (19). However, only a few
studies have utilized small-angle scattering techniques to
study mAb solutions, despite the need to understand their
protein-protein interactions and aggregation behavior.
Those studies addressed conformational changes due to
formulation excipients (20,21), the structure of antigen-
mAb complexes (22), and the interactions between two
mAbs with very small sequence variation but very different
viscosities (23).Submitted March 25, 2014, and accepted for publication May 6, 2014.
*Correspondence: PathakJ@medimmune.com or rhc@plmsc.psu.edu
Editor: James Cole.
 2014 by the Biophysical Society
0006-3495/14/07/0469/8 $2.00We report herein SANS and rheology data for a concen-
trated mAb solution that slowly aggregates at 40C, allow-
ing us to fully analyze the stable (before incubation) and
aggregated states. Access to the stable state allows the struc-
ture factor of the monomer to be studied in detail, thereby
allowing the form factor of mAb aggregates to be isolated
from the scattering of aggregated samples. The mAb solu-
tion of this study was previously characterized by rheology
experiments (24): a non-Newtonian character is elucidated
in the presence of a yield stress (minimum stress necessary
for the solution to flow at low shear rates) after prolonged
incubation at 40C, whereas the control samples are Newto-
nian liquids. Biophysical characterization measurements
confirmed the formation of aggregates after incubation at
40C: the percentage of monomer, determined using size-
exclusion chromatography (SEC), decreased within a few
days (~85% monomer left after 10 days); a slower decay
in the dynamic light scattering (DLS) autocorrelation func-
tion was observed for aggregated solutions that exhibit a
yield stress (24). Moreover, the concentration of aggregates
>2 mm measured by micro-flow imaging increased upon in-
cubation at 40C, but no significant changes were observed
in their size distribution (24).
The aggregates responsible for the non-Newtonian
character of mAb solutions were characterized in this study
using SANS. Analysis of the structure factor provides
information about intermolecular interactions in mAb
monomers that give rise to a reaction-limited aggregation
mechanism for the formation of very large aggregates
(submicrometer particles). The results suggest that mAb
monomers collide weakly several times, forming dynamichttp://dx.doi.org/10.1016/j.bpj.2014.05.015
470 Castellanos et al.reversible aggregates, whereas favorable interactions with
strong binding energy lead to irreversible aggregation.MATERIALS AND METHODS
The mAb studied here (25) is a fully humanized IgG1 (isoelectric point 8.6,
molecular mass 145 kDa) that slowly aggregates when incubated in its
formulation buffer at 40C. The mAb comes in vials as a lyophilized for-
mulation. SANS samples were prepared by reconstituting the lyophilized
powder with 2.17 mL of fresh deuterium oxide (D2O, 151882, Sigma
Aldrich, St. Louis, MO) to give a mAb concentration of 53 mg/mL. The
mAb formulation buffer contains 20 mM histidine buffer at pD 6.4 with
60 mg/mL of trehalose and 0.2 mg/mL of polysorbate-80 nonionic surfac-
tant. D2O is used to achieve better sample contrast in neutron scattering.
Samples are stored at 2–8C before the SANS measurements.
Samples were prepared at 5 mg/mL by diluting with fresh formulation
buffer, and at concentrations up to 228 mg/mL by using centrifugal filtra-
tion (Amicon Ultra-15, 50k MWCO filters, cat. no. UFC905024, EMD
Millipore, Billerica, MA) at 4000 relative centrifugal force. Additional
samples for stability studies were prepared by reconstituting with sterile
water for injection (cat. no. 918510, APP Pharmaceuticals, Lake Zurich,
IL) and incubating at 40C for approximately one month. This is the stan-
dard incubation temperature for accelerated mAb aggregation studies in the
biopharmaceutical industry. It is below 49C, where the unfolding of the
least thermally stable CH2 domain occurs. In addition, samples stored at
2–8C show 99% monomer with SEC, a single relaxation with DLS, and
a Newtonian response with steady shear rheology, and thus consist mostly
of monomer. However, samples incubated at 40C for 33–44 days have
70–83% monomer and show at least two exponential decays with DLS
and a non-Newtonian character in steady shear flow. We refer to sub-
micrometer particles as proteinaceous aggregates with length scales of
0.1–1 mm, according to the nomenclature in Narhi et al. (26).
The aggregated samples were dialyzed (Slide-A-Lyzer Cassette 10 kD
MWCO, cat. no. 66810, Thermo Scientific, Waltham, MA) for 12 h at
2–8C three times against a fresh solution containing the same excipients
as the original formulation but dissolved in D2O to achieve high contrast
in the SANS experiments. Protein concentration was assessed using absor-
bance at 280 nm in a NanoDrop 1000 spectrophotometer (Thermo Scienti-
fic) using an extinction coefficient of 1.45 cm2 mg1 (absorbance of 14.5
for a 1% solution using a 1 cm path length). All samples were degassed
for 30 min (9 inHg) before the SANS measurements. For filtering experi-
ments, we used 0.2 mm sterile filters with low protein binding (Acrodisc fil-
ter, cat. no. 4192, Gelman Sciences, Ann Arbor, MI; and Millex-GV Sterile
filter, cat. no. SLGV013SL, Millipore). The rheology experiments reported
here were performed in a cup-and-bob strain-controlled rheometer (LS-30,
Contraves, Zurich, Switzerland; currently sold and serviced by ProRheo,
Althengstett, Germany) at 25C; further details about this instrument and
the steady shear protocol can be found in Castellanos et al. (24). Electro-
phoretic mobility measurements were performed in a Zetasizer Nano Series
(Malvern Instruments, Malvern, United Kingdom) at 10 mg/mL and 25C
to determine an experimental charge of þ3.7e5 0.2e (where e is electron
charge; charge estimation assumes that the monomers are spherical parti-
cles with radius 5.1 nm) in the histidine buffer at pH 6.0. Aggregate content
was determined with UV-detection based high performance size exclusion
chromatography (HP-SEC Agilent 1100 series, Tosoh G3000SWXL Col-
umn, Santa Clara, CA) after sample dilution to 10 mg/mL. Circular dichro-
ism spectra were measured on a Jasco-815 spectropolarimeter (Jasco,
Easton, MD) using quartz cuvettes with a path length of 1 cm for the low
concentration (c % 10 mg/mL), and 0.1 mm for the high concentrations
(c R 100 mg/mL). Scans were performed at 20C from 350 nm to
240 nm using a speed of 20 nm/min, 0.5 nm data pitch, and 1 nm bandwidth.
Autocorrelation functions (DLS) were obtained using a DynaPro Plate
Reader (Wyatt Technology, Santa Barbara, CA; wavelength, l ¼ 830 nm;
scattering angle, 2q ¼ 158; wavevector, q ¼ 0.020 nm1) at 25C after
centrifuging samples in a well plate for 2 min at 200 rpm.Biophysical Journal 107(2) 469–476SANS measurements were performed on the NG-7 (30 m SANS) and
the NG-B (10 m SANS) beam lines at the National Institute of Standards
and Technology (NIST) Center for Neutron Research (NCNR, Gaithers-
burg, MD) using three different configurations by varying the detector
distance (1 m to 15.3 m) and the wavelength of neutrons (5 A˚ to
16 A˚) to access wavevectors ð~q; j~qj ¼ 4p sinðqÞ=lÞ in the range
0.001 A˚1 < q < 0.6 A˚1, where 2q denotes the scattering angle.
Although small-angle x-ray scattering (SAXS) can also be used to study
structure and interactions in proteins, SAXS measurements could induce
radiation damage in protein solutions and promote further aggregation
(27,28). Measurements were performed at 25C using standard quartz
cells with 1 mm path length. The scattering cross section was obtained
after correcting for detector efficiency, background, and empty cell scat-
tering, using the SANS reduction package from NCNR (NIST, Gaithers-
burg, MD) (29) implemented in Igor Pro (Wavemetrics, Portland, OR).
After obtaining the absolute intensity, incoherent scattering background
was subtracted and the high-q data (q > 0.3 A˚) were normalized using
Porod’s law (I ~ q4) (30).RESULTS AND DISCUSSION
Monomeric mAb solutions (before incubation at
40C)
For a monodisperse sample, the absolute cross section
dS=dU, or intensity depends on the number density
of monomers nm, the scattering amplitude fmðqÞ ¼
½rm  rsolvent
R
ei~q:~rd~r (where r is the scattering length),
the effective structure factor of the monomer SmðqÞ, and
the background B, as follows:
dS
dU
ðqÞ ¼ nm
jfmðqÞj2

SmðqÞ þ B ¼ nmPmðqÞSmðqÞ þ B:
(1)
PmðqÞ corresponds to the form factor of the monomer, and
the angled brackets denote an ensemble average. The exper-
imental data are normalized by fitting the equation for the
scattered intensity IðqÞ ¼ Aq4 þ B (Porod’s law), at high
q values (q > 0.3 A˚1), where the constant B accounts for
the incoherent background, and the factor A accounts for
the protein number density contribution. The normalized
data are reported as ðIðqÞ  BÞ=A, and this methodology is
consistent with the normalization method where the back-
ground is subtracted and the absolute intensity is divided
by concentration (see Figs. S1 and S2 in Supporting Mate-
rial). After normalization using Porod’s law, the scattered
intensity depends exclusively on the form factor and the
structure factor.
Fig. 1 shows the normalized scattered intensity for the
monomeric samples at different protein concentrations. The
form factor of the mAb was estimated using the normalized
data at 5 mg/mL, where intermolecular interactions are negli-
gible and SmðqÞy1. The experimental data were fitted using
Cryson (33,34) to the predicted scattering of a human IgG1
b12 crystal structure (Protein Data Bank 1HZH, crystallized
at pH 6.5) (31,32). The fitting considers a hydration shell
around the protein that has scattering properties different
from those of bulk water. Omission of the hydration shell
FIGURE 1 (a) SANS profiles of the mAb solution at four concentrations. The curve corresponds to the form factor Pm(q) fit for q> 0.01 A˚
1 (the fit to the
5 mg/mL data is quite good, reflected in c2 ¼ 1.2). Protein concentrations are as follows: 2285 6 mg/mL, 1055 2 mg/mL, 54.45 0.2 mg/mL, 5.45
0.1 mg/mL. (b) Form factor of an IgG molecule using the Y-shape model from Yearley et al. (23), the form factor of the PDB crystal structure (1HZH) and the
experimental data for our mAb at a concentration of 5 mg/mL. Details on determination of protein concentration, the parameters of the Y-shape model, and c2
values can be found in the Supporting Material.
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tallographic structures to scattering data, as shown by Sver-
gun and co-workers (33). Fitting with Cryson allows an
estimation of the scattering contrast of the hydration shell
(0.58 1010 cm2) and the average displaced solvent volume
(316 nm3) per molecule. Cryson also allows an estimation of
the radius of gyration using the Guinier approximation,
resulting in an experimental radius of gyration of Rg¼
5.2 5 0.5 nm for the monomer. Nonetheless, proteins in
solution are likely more flexible than the conformation sug-
gested by the crystal structure, and different pH or changes
in buffer excipients could lead to important conformational
changes (20). In these cases, the form factor might not always
correspond to the scattering expected from crystallographic
structures.
The Y-shape antibody form factor model recently derived
by Yearley et al. (23) did not successfully describe the
experimental scattering data (see Fig. 1 b), possibly because
features of the Fc (crystallizable) and Fab (antigen-binding)
domains at q > 0.1 A˚1 cannot be solved by assuming a
rectangular box with constant scattering density. Additional
details about the Y-shape model fits are presented in the
Supporting Material.
Using Eq. 1 and the form factor of the monomer PmðqÞ,
the structure factor of the monomer can be isolated. An
effective structure factor Sm, that accounts for the nonspher-
ical shape of proteins needs to be considered. However,
there are currently no models available to accurately calcu-
late the structure factor of anisotropic particles. One
approach is to use an average structure factor approximation
using an effective sphere diameter that has the same second
virial coefficient as the anisotropic system (29,36); another
alternative is to use the decoupling approximation (37). Theaverage structure-factor approximation has been used here,
where the effective size of the sphere was determined by
fitting a two-Yukawa potential (9,38,39) with repulsive
and attractive terms:
UðxÞ
kBT
¼
8>><
>:
N; 0<x<1
K1e
Z1ðx  1Þ
x
 K2e
Z2ðx  1Þ
x
; x>1:
(2)
Ki denotes the strength and Zi the range of the attractive
(i ¼ 1) and repulsive (i ¼ 2) interactions; x ¼ r=s is the
dimensionless form of the distance r; and s is the effective
hydrodynamic diameter. The repulsive part of the Yukawa
potential is related to the electrostatic interaction between
charged particles and depends on the effective charge
z (charge experienced by a molecule in solution) and the
Debye length k1, as follows (40):
UrepulsionðrÞ ¼ z
2ekðrsÞ
pε0εð2þ ksÞ2r
; r>s; (3)
where ε is the dielectric constant of water and ε0 the permit-
tivity of free space. Since the Debye length is known to
be 2.1 nm for the mAb solution of this study (ionic strength
of 20 mM), this parameter was kept fixed during the fitting.
Volume fractions f, are required to calculate the structure
factor from an intermolecular potential, and these were esti-
mated at each concentration c, using the hydrated volume
VH, of an IgG molecule obtained from the form factor fitting
using Cryson as f ¼ cNAVH=Mw, where NA is Avogadro’s
constant and Mw is the molecular mass. We estimatedBiophysical Journal 107(2) 469–476
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tions of 54 mg/mL, 105 mg/mL, and 228 mg/mL, respec-
tively. The volume fraction can also be estimated using
the partial specific volume of an IgG1 (41), and the mass
of hydration water per mass of protein can be estimated
from Cryson. The latter approach gives very similar results
to those estimated using the hydrated volume (4% differ-
ence). Both methodologies properly account for hydration
in calculating volume fractions (42). The structure factor
for a two-Yukawa potential has been solved using the
hypernetted chain closure (43) and the mean spherical
approximation (38), and the latter was used here. The effec-
tive structure factor determined experimentally is depicted
in Fig. 2 a along with the fitting using the two-Yukawa
potential (Eq. 2).
Subtle shoulders are observed in the experimental struc-
ture factor at q ~0.07 A˚1, corresponding to an average
interparticle separation distance (center-to-center distance)
of ~9.0 nm. Moreover, a decrease in Sðq/0Þ with concen-
tration suggests that repulsive interactions dominate the
scattering. However, the structure factor fit was unsuccess-
ful using an exclusively repulsive potential with the known
parameters of charge and Debye length. A satisfactory
fitting of the experimental structure factor was found using
the two-Yukawa potential with a long-range repulsion and
a short-range attraction. The parameters obtained from the
fitting are as follows: K1 ¼ 4:050:1, Z1 ¼ 19:050:5,
K2 ¼ 0:2050:03, and Z2 ¼ 4:350:7, using an effective
diameter of 9.2 5 0.2 nm for all the concentrations
studied. Using these parameters, the charge of the particle
is þ5e 51e, in good agreement with the þ3.7e from elec-
trophoretic mobility data.
The fitting describes the data successfully for the medium
concentrations, but significant deviations occur for the
highest concentration in the q range 0.05 A˚1 < q <FIGURE 2 (a) Experimental structure factor of the mAb solution at different
interaction potential between mAb monomers in solution. Inset depicts the repu
Biophysical Journal 107(2) 469–4760.1 A˚1. These q values correspond to the region where
the nearest-neighbor peak would occur, and its amplitude
would increase with particle concentration, since the
neighbor distances are constrained in crowded environ-
ments. However this peak is very weak in the experimental
structure factor, which could be due to the anisotropy of the
IgG molecules as they will have multiple interparticle sepa-
ration distances. Since this model assumes an isotropic
potential using an effective sphere, it is expected that devi-
ations will occur in the region where the shape of the parti-
cle becomes important. Monte Carlo simulations suggest
that anisotropy could affect the intensity from interparticle
correlations as concentration increases (44). In addition,
the decoupling approximation applied to a Y-shape model
suggests that deviations due to the anisotropy of the particle
should occur at q > 0.05 A˚1 (23), in agreement with our
results. Although the model assumes an isotropic potential
for non-spherical particles, it describes very well the data
for all concentrations in the low-q region (q < 0.05 A˚1),
where anisotropic effects are less significant. Moreover,
the repulsive part of the potential agrees with the expected
values of charge and ionic strength, and the data were suc-
cessfully fitted at all concentrations using the same interac-
tion parameters.
Aweak repulsive barrier (~0.04 kBT) and a primary mini-
mum (3.8 kBT) are estimated using the two-Yukawa
potential. The weak repulsive barrier suggests that proteins
can easily fall into the primary minimum, where they will
aggregate reversibly upon contact: at room temperature and
3.8 kBT of energy, proteins can diffuse over the energy
barrier after aggregation and come back to the monomeric
state on timescales of ~30 ms (45,46). Because of the short
lifetime of these aggregates, they can be considered revers-
ible at timescales of normal interest. Irreversible aggregates
will only form when a more favorable contact betweenconcentrations and fitting to a two-Yukawa potential (Eq. 2). (b) Effective
lsive interaction and the weak repulsive barrier for reversible aggregation.
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Although the average interaction potential would suggest
that only reversible aggregation should occur, proteins have
a rich variety of interactions from their amino acid sequence,
leading to different sites that could interact strongly when a
favorable configuration is found. In fact, the mAb studied
here has three mutations in the crystallizable (Fc) domain,
and with these specific changes in the sequence, the mAb
showed a decrease in stability compared to the wild-type
protein (without mutations) (25). It is possible that these
mutations in the Fc region could lead to specific interactions
with a very deep energy minimum and therefore play an
important role in the irreversible aggregation of the
molecule.Scattering from aggregated antibody solutions
(after incubation)
The scattered intensity of aggregated solutions is com-
pared to the intensity of stable mAb solutions in Fig. 3 a.
The monomer form factor dominates the scattering at
q > 0.1 A˚1 in all samples. At intermediate q values
(0.006 A˚1 < q < 0.1 A˚1), the intensity of monomeric
samples approaches a plateau as q decreases, whereas the
scattering of the aggregated samples shows a continuous
increase in the intensity. At the smallest q values (q <
0.006 A˚1), a power-law behavior is observed in aggregated
samples.
For a system consisting of aggregates (agg) and mono-
mers (m), the contribution of aggregates to the scattering
can be estimated. Considering all types of aggregates as a
single population with low number density compared to
that of the monomer, and assuming that the structure factor
of the aggregates does not contribute to the scattering at the
length scales studied ðSaggðqÞz1Þ, the total scattering of
aggregated samples can be estimated as:FIGURE 3 Scattered intensity of aggregated mAb solutions at different mon
samples. (b) Isolated aggregate contribution to the scattering. Aggregates were f
in the legend.dS
dU
ðqÞznmPmðqÞSmðqÞ þ naggPaggðqÞ þ B: (4)
Here, nagg corresponds to the number density of aggregates
and PaggðqÞ is the form factor of the aggregates. In Eq. 4,
it is assumed that each population can be effectively sepa-
rated, and interactions involving aggregates are rather
weak at the length scales studied. As shown later, the aggre-
gates larger than 0.2 mm were effectively removed by
filtering without affecting the scattering of the smaller spe-
cies, supporting the validity of these assumptions. By sub-
tracting the contribution of monomers (Eq. 1) to the total
scattered intensity (Eq. 4), the contribution of aggregates
can be isolated (see Fig. 3 b). The resulting scattering can
be separated into a low-q region, q < 0.006 A˚1, dominated
by a power-law response and an intermediate-q region,
0.006 A˚1 < q < 0.04 A˚1. The low-q region can be
described by a power law with an average slope of 2.3 5
0.4. Since filtering through a 0.2 mm filter removes the
low-q upturn, this low q region of the scattering is attributed
to submicrometer aggregates. Therefore, the slope corre-
sponds to the fractal dimension of the larger aggregates
with d ¼ 2p/q > 0.1 mm that were detected by SANS.
The fractal dimension of 2.3 suggests that aggregates are
formed by a reaction-limited aggregation (RLA) (47) or
slow flocculation process (48), which occurs in the presence
of a repulsive barrier. Therefore, antibody molecules collide
hydrodynamically several times by Brownian motion, but
they aggregate irreversibly only after a favorable interaction
is achieved. Although hard colloidal particles have a fractal
dimension of 2.1 (47,49,50), proteins are not rigid spheres
and it is expected that they form slightly more dense struc-
tures. Previous studies have revealed the fractal morphology
of mAb aggregates under acidic conditions (51,52). A fractal
dimension of 2.565 0.3 was reported for IgG1 aggregates
formed under dilute conditions, c ¼ 1 mg/ml to 16 mg/mL,omer concentrations. (a) Aggregated samples are compared to monomeric
ormed by incubating the solution at 40C during the time periods specified
Biophysical Journal 107(2) 469–476
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small-angle light scattering (52–54). A slightly smaller
fractal dimension was determined here at higher protein
concentrations than previously reported.
The fractal aggregates can be removed by filtering
through a 0.2 mm filter, eliminating the low-q upturn of
aggregated samples. On the contrary, features of the aggre-
gates at q > 0.005 A˚1 or d < 0.1 mm persist (nanometer
aggregates). Fig. 4 a depicts the contribution of aggregates
to the intensity before and after filtration. The size of the ag-
gregates that persist after filtration can be obtained using the
Guinier analysis (55), and an average Rg ¼ 9.55 3.0 nm is
determined.
Previous studies have demonstrated that irreversible
aggregates contribute to an increase in the low shear rate
viscosity and disrupt the monotonic dependence of viscosity
with concentration (56). Fig. 4 b shows the effect of filtra-
tion on the rheology of the mAb solution. We measured
the rheology of the mAb in its buffer with H2O, because
the incubation studies were performed under those condi-
tions, and H2O is a more relevant solvent for antibodies
than D2O. Nevertheless, the results of Fig. 4 b are reproduc-
ible in D2O buffer (see Fig. S5). The yield stress, upturn in
viscosity at low shear rates, is eliminated after filtration,
which also removes fractal aggregates >~0.2 mm (submi-
crometer particles). These aggregates contribute to the
low-q upturn in the scattering. Hence, submicrometer
particles with fractal characteristics are responsible for the
yield stress in this mAb solution. Oligomers do not
contribute to the yield stress and display a Newtonian
response to shear. However, low shear rheology is sensitive
to the presence of submicrometer particles, and thus it is
important to measure flow curves instead of a single fre-
quency or shear rate. Ultrasonic shear rheometry at one
fixed frequency 10MHz is not ideal for correlating with pro-
tein stability (57).FIGURE 4 (a) Effect of filtration on the scattering of a mAb solution at 58 mg
rate _g, of the mAb solution in a. Lines correspond to the viscosities expected
sY ¼ 4:551:1 mPa. hN is the viscosity at high rates.
Biophysical Journal 107(2) 469–476The mAb aggregates formed upon incubation at 40C
have different features at nanometer and submicron length
scales. SEC has shown that oligomers of this particular
mAb formulation form within a few days upon incubation
at 40C (24). It has also been suggested that an early step
in the aggregation pathway of this mAb is the formation
of trimeric species (58), which might correspond to the
small oligomers detected here by SANS with an average
Rg of ~10 nm. The large fractal aggregates are removed
by filtering (0.2 mm), as indicated by the absence of the
power-law behavior at low q. Moreover, these fractal submi-
crometer particles are responsible for the non-Newtonian
behavior (i.e., yield stress) observed in the steady shear
rheology measurements. The yield stress is only observed
after several days of incubation at 40C when oligomers
had already formed, in agreement with a slow flocculation
process to form fractal aggregates. These conclusions agree
qualitatively with the results of Andersen et al. (59) for a
different IgG1, where fast formation of small aggregates
occurred, followed by slow formation of larger fractal ag-
gregates with no significant conformational changes in the
protein. The RLA mechanism has also been observed
recently in other IgG molecules, and our neutron scattering
data is fully consistent with light scattering results (52,60).
Moreover, the weak repulsive interaction between mAb
monomers is in agreement with RLA, as particles collide
hydrodynamically several times but slowly aggregate only
after a favorable interaction site is found.CONCLUSIONS
In conclusion, stable and aggregated monoclonal antibody
solutions have been characterized using small-angle neutron
scattering, and the aggregated structure responsible for the
non-Newtonian character has been identified. For the first
time to our knowledge, a connection between the low-q/mL incubated for 44 days at 40C. (b) Viscosity hð _gÞ, as a function of shear
for a Newtonian fluid (red) and a Bingham fluid (black) with yield stress
mAb Aggregation Mechanism Using SANS 475upturn in the neutron scattering data and the non-Newtonian
rheology of aggregated monoclonal antibody solutions has
been established. The intermolecular interactions between
mAb monomers at medium and high concentrations can
be described using a two-Yukawa potential, and the results
of the analysis support a reaction-limited aggregation
mechanism by which large irreversible aggregates are
formed. The combination of a long-range repulsion and a
short-range attraction gives an intermolecular interaction
with a weak repulsive barrier of 0.04 kBT and a primary en-
ergy minimum of 3.8 kBT, and therefore, mAb monomers
form weak aggregates upon contact.
Protein aggregates formed upon incubation at 40C can
be classified as oligomers with an average Rg of 10 nm
and fractal aggregates with sizes exceeding 0.1 mm.
Whereas the formation of oligomers occurs within a few
days according to the SEC data, larger fractal aggregates
are formed after several days by a slow flocculation of olig-
omers that resembles the RLA process observed for col-
loids. Filtration with a 0.2 mm filter removed the fractal
aggregates, which eliminated both the low-q upturn in scat-
tered intensity and the yield stress in shear flow. Submi-
crometer particles that are fractal in nature are responsible
for the non-Newtonian character observed in steady shear
rheology and the low wavevector upturn in small-angle
scattering.SUPPORTING MATERIAL
Five figures and one table are available at http://www.biophysj.org/
biophysj/supplemental/S0006-3495(14)00445-7.
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